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malabsorption and requires parenteral nutrition (PN) to maintain
energy, ﬂuid and electrolyte balance. Neonatal causes of IF
include extensive intestinal resections resulting in short bowel
syndrome, congenital enteropathies affecting mucosal function
and severe intestinal motility disorders due to enteric nerve or
muscle dysfunction. In the adult population, IF typically develops
after major resection of affected intestine in inﬂammatory bowel
disease or intestinal ischemia. PN is central to the management of
IF, ideally serving as a nutritional bridge until intestinal auton-
omy is restored through intestinal adaptation. Notwithstanding
its vital therapeutic importance, PN has been associated with
hepatobiliary complications in this setting (i.e. IF-associated liver
disease, IFALD) since its introduction in the late 1960s.
Children on long-term PN are especially affected by IFALD,
with prevalence rates ranging from 22% to 50%. Four percent of
all children on PN will eventually die or require intestinal or
multivisceral transplantation because of IFALD [1]. In infants,
the predominant histological feature of IFALD is cholestasis,
which appears to relate to immaturity of the hepatobiliary
system and septic complications. In older children and adults,
the dominant histological ﬁnding is steatosis. Pediatric IFALD
can rapidly progress to cirrhosis with all the associated com-
plications. Risk factors for IFALD include prematurity (especially
in case of concomitant necrotizing enterocolitis), small bowel
bacterial overgrowth, bacterial infections, inability to tolerate
any enteral nutrition, and formulation or mode of administration
of PN.Journal of Hepatology 20
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Open access under CC BY-NC-ND license.Bile salts are signaling molecules that activate speciﬁc recep-
tors during their enterohepatic circulation (Fig. 1). Disruption of
the enterohepatic circulation is a frequent phenomenon in IFALD,
as a consequence of hepatocellular cholestasis, absence of enteral
feeding-induced gallbladder contraction and intestinal motility,
and (partial) loss of the ileum. In this issue, Mutanen et al. explore
a consequence of perturbed enterohepatic cycling in IFALD by
studying serum levels of the bile salt-induced enterokine FGF19.
They report a negative association between FGF19 levels and
severity of IFALD, with potential therapeutic implications [2].
FGF19 is an endocrine-acting member of the family of ﬁbrob-
last growth factors (FGF). Its intestinal expression is restricted to
the ileum, and is induced following reclamation of bile salts from
the intestinal lumen. In the enterocyte, absorbed bile salts subse-
quently activate the farnesoid X receptor (FXR). This ligand-
activated transcription factor (abundantly expressed in ileum
and liver) controls expression of numerous genes including
FGF19 and regulates various processes in the small intestine
and liver, with protection of the liver against detrimental effects
of bile salt overload [3]. After secretion into the portal circulation,
FGF19 reaches the liver, where it binds to a hepatocytic cell
surface receptor (FGF Receptor 4). In the hepatocyte, FGF19
signaling acts in accord with the transcriptional repressor SHP
to downregulate expression of a key enzyme related to the con-
version of cholesterol into bile salts, thus providing negative
feedback control of bile salt synthesis [3]. FGF19 has also been
implicated in the regulation of energy and lipid metabolism,
compensatory liver growth and possibly (by counteracting
NF-jB signaling) control of inﬂammation [3,4]. Studies in mice
revealed that FGF19 – or constitutive ileal FXR activation – pro-
tects against cholestatic liver injury induced by bile duct ligation
[5]. Given the plethora of effects of the FXR-FGF19 axis on pro-
cesses disturbed in IFALD, it is conceivable that dysfunction of
this axis may contribute to the pathogenesis of IFALD. This notion
is supported by observations in piglets receiving total PN, where
enteral administration of bile salts prevented intestinal atrophy
and cholestatic liver injury [6].
To explore potential dysfunction of the FXR-FGF19 axis,
Mutanen et al. retrospectively studied 52 pediatric patients with15 vol. 62 j 1231–1233
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Fig. 1. Dysfunctional FXR/FGF19 signaling may be involved in the pathogenesis of IFALD. In health, bile salts activate the bile salt receptor FXR in the ileum and liver
during their enterohepatic cycle. Ileal FXR controls intestinal barrier integrity and prevents bacterial overgrowth, thus limiting portal entry of microbial products that can
activate the hepatic innate immune system. Bile salt-induced elevation of circulating FGF19 levels represses hepatic bile salt synthesis. Hepatic FXR further acts as a
safeguard against bile salt toxicity by controlling import and efﬂux of bile salts. In IFALD, enterohepatic bile salt signaling is presumably impaired as a consequence of
intestinal failure. The consequential barrier dysfunction and bacterial overgrowth, especially in cases of ileocaecal resection, results in translocation of microbial products
that activate resident macrophages in the liver. Subsequent release of pro-inﬂammatory cytokines like IL-6 and TNFa disturbs bile salt homeostasis by interfering with bile
salt export and FXR function in general. Moreover, the inhibition of bile salt synthesis may be released due to impaired activation of the ileal FXR-FGF19 axis. Liver injury
may arise from intrahepatic accumulation of toxic bile salts, and impaired FXR/FGF19-mediated liver repair. Parenteral nutrition may have direct roles in these pathogenic
events by activating Kupffer cells and antagonizing FXR signaling.
EditorialIFALD due to short bowel syndrome (69%) or dysmotility disor-
ders (31%) [2]. Fifty percent of these patients had residual ileum.
Serum FGF19 levels were lower (3-fold) in IFALD patients than
in age- and sex-matched controls, and were particularly low in
cases of ileal resection, portal inﬂammation or ﬁbrosis.
Furthermore, serum levels of inﬂammatory cytokines, TNFa and
IL-6, were elevated in patients with IFALD. At histological exami-
nation of liver biopsies (available in 39 patients), ﬁbrosis was pre-
sent in 62%, steatosis in 46%, portal inﬂammation in 18% and
cholestasis in 13%. Serum FGF19 levels were negatively associated
with the grade of portal inﬂammation and METAVIR ﬁbrosis stage,
serum TNFa and IL-6, as well as serum cholesterol precursors.
Although levels of a serum marker for bile salt synthesis (e.g.
7a-hydroxy-4-cholesten-3-on) were not determined, these data
suggest that bile salt synthesis is elevated in patients with low
serum FGF19 and that this is accompanied by compensatory
cholesterol neo-synthesis to replenish the bile salt precursor pool.
De-repression of bile salt synthesis due to lowered FGF19
levels, combined with inﬂammation/PN-related lowering of the
hepatocytic canalicular bile salt transporter ABC-B11 (i.e. ‘‘bile
salt export pump’’) may result in intra-hepatocytic bile salt accu-
mulation and cholestatic liver injury. Although a causal role of
FGF19 in the histological abnormalities in IFALD cannot be
inferred from the study of Mutanen et al. [2], it is conceivable that1232 Journal of Hepatology 2015partial loss of the ileum, and accordingly impaired activity of the
FXR–FGF19 axis, may contribute to progressive liver disease.
Future animal experiments in Fgf15- or intestine-speciﬁc Fxr
knockout mice subject to an IFALD-inducing protocol may shed
light on a potential initiating or contributory role of the FXR–
FGF19 axis. Such insights may also provide a rationale for
pharmacological intervention.
The ﬁndings of Mutanen et al. come at a time in which FXR is
drawing much attention from hepatologists worldwide. For some
time, gut microbiota have been appreciated as key determinants
of intestinal inﬂammation and impaired intestinal barrier func-
tion, and FXR has recently been implicated in the prevention of
intestinal bacterial overgrowth, maintenance of intestinal barrier
integrity [7] and pathogenesis of Crohn’s disease [8–10].
Accumulating evidence indicates that the gut microbiota and
the ‘‘gut–liver axis’’ are also playing a key role in chronic inﬂam-
matory disease of the liver [11] (Fig. 1). In mice with global deﬁ-
ciency of Fxr, restored intestinal FXR expression is sufﬁcient to
maintain bile salt homeostasis through the FGF15 axis and to pre-
vent hepatic inﬂammation and progressive liver disease with
hepatocellular carcinoma [12]. Apart from preventing derange-
ment of bile salt homeostasis, restored intestinal barrier function
and anti-inﬂammatory effects through inhibition of NF-jB are
likely to be involved in these beneﬁcial effects [4,13].vol. 62 j 1231–1233
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Potentially relevant for the work of Mutanen et al. [2], both
intestinal compromise (mimicked by oral administration of the
bowel irritant dextran sodium sulphate) and intravenous PN
administration are required to induce cholestatic liver injury in
a novel mouse model of IFALD [14]. Key features of this model
are increased intestinal permeability, elevation of portal
lipopolysaccharide levels, Kupffer cell activation and transcrip-
tional repression of hepatobiliary transporters. Of note, in this
model, liver injury could be prevented by ﬁsh oil-based PN, and
could be provoked by addition of stigmasterol to the ﬁsh oil-
based PN. Stigmasterol is a plant sterol in soybean oil-based PN
that can act as an FXR antagonist [15].
FXR controls a number of processes that are deranged in the
multifactorial origin of IFALD. Thus, the presumed impairment
of bile salt signaling in IFALD may be prone to stimulation with
FXR agonists in patients with residual ileum. In recently published
randomized controlled trials, the FXR agonist 6-ethyl-chenodeoxy-
cholic acid (Obeticholic acid) improved biochemical parameters in
primary biliary cirrhosis patients with inadequate response to
ursodeoxycholic acid alone [16], and led to markedly improved
liver histology in patients with non-alcoholic steatohepatitis [17].
In fact, the FDA has just granted ‘‘Breakthrough Designation’’ for
Obeticholic acid for the treatment of non-alcoholic steatohepatitis
with liver ﬁbrosis. ‘‘Breakthrough Designation’’ is a relatively new
scheme that is intended to streamline drug development for highly
promising agents and is awarded to a drug in relation to a seriou-
s or life-threatening disease based on preliminary clinical evidence
which suggests substantial improvement over existing therapies
[18]. Nevertheless, a word of caution should be given here, in the
sense that these studies (inherent to their short-term follow-up
design) did not reveal improvement of hard clinical endpoints.
Also, there was a deterioration of the serum lipid proﬁle during
Obeticholic acid, in part due to the inhibition of cholesterol con-
version into bile salts. Obviously, cardiovascular rather than liver
disease is the major cause of morbidity and mortality in non-alco-
holic steatohepatitis.
Returning to the study of Mutanen et al. [2], the merit of this
study is that in a relatively large number of patients with this rare
disease, low serum FGF19 are clearly established. The reported
negative correlations between serum FGF19 and length of
resected ileum as well as severity of the liver disease do not prove
causality but could very well be secondary to altered enterohep-
atic circulation of bile salts. Likewise, it is conceivable that
reduced intestinal FXR activation is an important player in
IFALD pathogenesis, considering its key role in intestinal
permeability. In conclusion, the study of Mutanen et al. [2] should
stimulate further research to elucidate the role of the FXR-FGF19
axis in IFALD, before any therapeutic trials with FGF19 can be
considered [19].Conﬂict of interest
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